1. Introduction {#s0005}
===============

Support Vector Machine (SVM), a machine learning technique implied in the area of time series prediction and classification [@bb0155], [@bb0180] has widely been applied in the life science fields, especially in Bioinformatics. It can handle nonlinear classification tasks efficiently by mapping the samples into a higher dimensional feature space by using a nonlinear kernel function. Since the SVM approach is data-driven and model-free, it has important discriminating power for classification. This characteristic of SVM is obvious in cases where the sample sizes are negligible and numerous variables are involved (high-dimensional space).

Expression profile come under such a category, which contain a large number of attributes (genes). This type of expression data is used to predict the type and occurrence of the disease in a patient [@bb0195]. An important aspect while analyzing such type of expression data is the feature selection or dimensionality reduction. Most algorithms lose their potency when genes are large in number with different time series data or dimensionality [@bb0035].

To accomplish the task of dimensionality reduction a modified version of SVM known as SVMRFE (Support Vector Machine Recursive Feature Elimination) has been used in this work. SVMRFE was used to identify the most discriminatory target gene in four different microarray data samples of type II diabetes. These samples have been taken from the Gene Expression Omnibus database (GEO) [@bb0065] and Diabetes Genome Anatomy Project (DGAP) (<http://www.diabetesgenome.org/>). The idea was to build a model wherein the least important features (genes) can be eliminated at each iterative step based on the weight assigned to each gene through SVM. The genes identified through this approach were then classified as essential and non-essential genes. The protein-protein interaction of these non-essential genes revealed vital information regarding interacting proteins. Functional enrichment about these proteins shed a light on their regulatory pathways associated with type II diabetes which can be further explored and confirmed using experimental approach.

2. Materials and methods {#s0010}
========================

2.1. Collection of data sample {#s0015}
------------------------------

71 samples from Pancreatic Islet and Skeletal muscle of *Homo sapiens* were collected from the GEO and DGAP. Out of these 37 samples are of normal human beings and 34 are of diabetic humans. [Table 1](#t0005){ref-type="table"} shows the detail description of each of the data sets which were undertaken for studies.Table 1Microarray dataset undertaken for studies.Table 1SourceDataNo. of samplesNo. of genesCountryNormalDiabeticGEOEffect of insulin infusion on human skeletal muscle [@bb0165]6622,215SwedenDGAPHuman pancreatic islets from normal and Type 2 diabetic subjects (A) [@bb0090]7522,191Caucasian and AsianDGAPHuman pancreatic islets from normal and Type 2 diabetic subjects (B) [@bb0090]7522,550DGAPHuman skeletal muscle - type 2 diabetes [@bb0145]171822,177Sweden

Fisher linear discriminant was applied to all the above-mentioned data sets to rank them based on the Fischer score [@bb0105] which was continued with a redundancy reduction step to reduce the redundant data in the microarray dataset [@bb0110]. The gene number present in each data set was still high. A *t*-test [@bb0015] with a significance level of 0.05 was applied to the datasets to filter out the genes which are not involved in causing type II diabetes. After this reduction step SVMRFE approach (with linear kernel function and 6 subsets of the training data) [@bb0120] was applied to train the data samples for 5 iterations. As a result, discriminatory genes based on the weighted ranking were obtained. The identified genes were identified as being essential and non-essential using the database of essential genes. A gene interaction and pathway analysis of the potential non-essential genes was performed to identify the novel targets for type II diabetes ([Fig. 1](#f0005){ref-type="fig"})Fig. 1Flow chart of the analysis.Fig. 1

3. Result and discussion {#s0020}
========================

3.1. *t*-test analysis {#s0025}
----------------------

For each of the T2D datasets, a *t*-test analysis was performed with a significance level of 0.05. As a result, there was a high dimensionality reduction in each dataset ([Table 2](#t0010){ref-type="table"}). The genes rejecting the null hypothesis were obtained for each of the data samples. [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"} show the corresponding p-values of all the genes which have rejected the null hypothesis at significance level of 0.05. The [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"} represent graphically the p-value of all the genes in the four datasets under consideration. The p-value for most of the genes was above the significance level value of 0.05. This represents that these genes have almost the same expression value in the normal and diseased and may not be involved in causing the disease.Fig. 2p-Value corresponding to all the genes in the training set for dataset "GSE7146".Fig. 2Fig. 3p-Value corresponding to all the genes in the training set for dataset "human pancreatic islets from normal and type II diabetic subjects (A)".Fig. 3Fig. 4p-Value corresponding to all the genes in the training set for dataset "human pancreatic islets from normal and type II diabetic subjects (B)".Fig. 4Fig. 5p-Value corresponding to all the genes in the training set for dataset "human skeletal muscle-type II diabetes".Fig. 5Table 2Number of input and output genes from each dataset for *t*-test analysis.Table 2Name of datasetNo of inputted genesNo of genes rejecting the null hypothesisEffect of insulin infusion on human skeletal muscle122324Human pancreatic islets from normal and type II diabetic subjects (A)121017Human pancreatic islets from normal and type II diabetic subjects (B)80321Human skeletal muscle-type II diabetes123828Table 3*p*-value of genes following the alternative hypothesis for the dataset "GSE7146".Table 3Probe idGenep-Value213524_s\_atG0/G1switch 20.00001216599_x\_atSolute carrier family 22 (organic anion transporter), member 60.00005207295_atSodium channel, non-voltage-gated 1, gamma0.0001218409_s\_atDnaJ (Hsp40) homolog, subfamily C, member 10.0003203221_atTransducin-like enhancer of split 1 (E (sp1) homolog, (*Drosophila*)0.0004210452_x\_atCytochrome P450, family 4, subfamily F, polypeptide 20.001201630_s\_atAcid phosphatase 1, soluble0.001207955_atChemokine (C-C motif) ligand 270.002208507_atOlfactory receptor, family 7, subfamily C, member 20.002210889_s\_atFc fragment of IgG, low affinity IIb, receptor (CD32)0.002207732_s\_atDiscs, large homolog 3 (neuroendocrine-dlg, *Drosophila*)0.002220636_atDynein, axonemal, intermediate polypeptide 20.002205863_atS100 calcium binding protein A120.002205603_s\_atDiaphanous homolog 2 (*Drosophila*)0.003220979_s\_atST6 (alpha-*N*-acetyl-neuraminy l-2, 3-beta-galactosy l-1, 3) -*N*-acetylgalactosaminide alpha-2, 6-sialyltransferase 50.003206310_atSerine peptidase inhibitor, Kazal Type II (acrosin-trypsin inhibitor)0.004210442_atInterleukin 1 receptor-like 10.004201214_s\_atProtein phosphatase 1, regulatory subunit 70.004220385_atJunctophilin 20.004205490_x\_atGap junction protein, beta 3, 31 kDa (connexin 31)0.004213772_s\_atGolgi-associated, gamma adaptin ear containing, ARF binding protein 20.004213950_s\_atProtein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma)0.004201681_s\_atDiscs, large homolog 5 (*Drosophila*)0.004220782_x\_atKallikrein-related peptidase 120.004Table 4p-Value of genes following the alternative hypothesis for the dataset "human pancreatic islets from normal and type II diabetic subjects (A)".Table 4Probe idGenep-Value207406_atCytochrome P450, family 7, subfamily A, polypeptide 10.0003214046_atFucosyltransferase 9 (alpha (1,3) fucosyltransferase)0.0004213980_s\_atC-terminal binding protein 10.0005202854_atHypoxanthine phosphoribosyltransferase 10.0005215300_s\_atFlavin containing monooxygenase 50.0007212894_atSuppressor of var1, 3-like 1 (*S. cerevisiae*)0.0012202605_atGlucuronidase, beta0.0017203196_atATP-binding cassette, sub-family C (CFTR/MRP), member 40.0021205633_s\_atAminolevulinate, delta-, synthase 10.0022207673_atNephrosis 1, congenital, Finnish type (nephrin)0.0027209759_s\_atEnoyl-CoA delta isomerase 10.003208926_atSialidase 1 (lysosomal sialidase)0.003205627_atCytidine deaminase0.004210284_s\_atTGF-beta activated kinase 1/MAP3K7 binding protein 20.004213931_atInhibitor of DNA binding 2, dominant negative helix-loop-helix protein0.0043213426_s\_atCaveolin 20.0047221572_s\_atSolute carrier family 26, member 60.0049Table 5p-Value of genes following the alternative hypothesis for the dataset "human pancreatic islets from normal and type II diabetic subjects (B)".Table 5Probe idGenep-Value227787_s\_atThyroid hormone receptor-associated protein 60.0001222478_atVacuolar protein sorting 36 (yeast)0.0002230329_s\_atNudix (nucleoside diphosphate linked moiety X) -type motif 60.0003226424_atCalcyphosine0.0003225491_atSolute carrier family 1 (glial high affinity glutamate transporter), member 20.0004225016_atAdenomatosis polyposis coli down-regulated 10.0005243043_atRAD50 interactor 10.0008224573_atRibonuclease, RNase K0.0012228133_s\_atMyosin, heavy polypeptide 11, smooth muscle0.0013225108_atAlkylglycerone phosphate synthase0.0013224865_atMale sterility domain containing 20.0024231880_atFamily with sequence similarity 40, member B0.0026241739_at2-oxoglutarate and iron-dependent oxygenase domain containing 10.003228036_s\_atF-box protein 20.0031223978_s\_atCardiolipin synthase 10.0032244706_atProtein-L-isoaspartate ([d]{.smallcaps}-aspartate) *O*-methyltransferase domain containing 10.0033237718_atEukaryotic translation initiation factor 4E0.0033222999_s\_atCyclin L20.0038230318_atSerpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10.0039222408_s\_atYippee-like 5 (*Drosophila*)0.004224954_atSerine hydroxymethyltransferase 1 (soluble)0.0046Table 6p-Value of genes following the alternative hypothesis for the dataset "human skeletal muscle-type II diabetes".Table 6Probe idGenep-Value219572_atCa ++-dependent secretion activator 20.0002204447_atLeucine zipper, putative tumor suppressor family member 30.0002221410_x\_atProtocadherin beta 30.0003201764_atTransmembrane protein 106C0.0005201429_s\_atRibosomal protein L37a0.0008204761_atUSP6 N-terminal like0.001219642_s\_atPeroxisomal biogenesis factor 5-like0.001218592_s\_atCat eye syndrome chromosome region, candidate 50.001210835_s\_atC-terminal binding protein 20.001216695_s\_atTankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase0.001208067_x\_atUbiquitously transcribed tetratricopeptide repeat containing, Y-linked0.001209400_atSolute carrier family 12 (potassium/chloride transporters), member 40.001201262_s\_atBiglycan0.001203171_s\_atRibosomal RNA processing 8, methyltransferase, homolog (yeast)0.002207131_x\_atGamma-glutamyltransferase 10.002219464_atCarbonic anhydrase XIV0.002206345_s\_atParaoxonase 10.002210907_s\_atProgrammed cell death 100.002202641_atADP-ribosylation factor-like 30.002204969_s\_atRadixin0.003222289_atPotassium voltage-gated channel, Shaw-related subfamily, member 20.003210318_atRetinol binding protein 3, interstitial0.003219301_s\_atContactin associated protein-like 20.004203116_s\_atFerrochelatase0.004207242_s\_atGlutamate receptor, ionotropic, kainate 10.004214005_atGamma-glutamyl carboxylase0.004215529_x\_atDIP2 disco-interacting protein 2 homolog A (*Drosophila*)0.004

3.2. Identification of best-ranked genes from SVMRFE {#s0030}
----------------------------------------------------

The subsets of genes based on the *p*-value were given as an input to the support vector machine. Recursive Feature Elimination (RFE) is an iterative procedure for SVM classifier. The recursive feature elimination algorithm of the support vector machine assigns a weight to each gene. The weight was calculated based on the expression value of genes in the disease and the normal sample for all the dataset. The algorithm classified the genes (with a classification accuracy of 83.9%) based on the descending order of the weight. Then it generated the list of genes which were found to be the most discriminatory in the normal and disease samples ([Table 7](#t0035){ref-type="table"}, [Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}). The outline for SVMRFE in the linear kernel is presented below:Table 7Best ranked genes for dataset "GSE7146".Table 7Gene nameG0/G1switch 2Transducin-like enhancer of split 1 (E (sp1) homolog, *Drosophila*)Acid phosphatase 1, solubleDnaJ (Hsp40) homolog, subfamily C, member 1Golgi-associated, gamma adaptin ear containing, ARF binding protein 2Protein phosphatase 1, regulatory subunit 7Interleukin 1 receptor-like 1Discs, large homolog 5 (*Drosophila*)Cytochrome P450, family 4, subfamily F, polypeptide 2Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma)Gap junction protein, beta 3, 31 kDa (connexin 31)Diaphanous homolog 2 (*Drosophila*)Olfactory receptor, family 7, subfamily C, member 2Solute carrier family 22 (organic anion transporter), member 6Serine peptidase inhibitor, Kazal Type II (acrosin-trypsin inhibitor)Chemokine (C-C motif) ligand 27Dynein, axonemal, intermediate chain 2Junctophilin 2Kallikrein-related peptidase 12S100 calcium binding protein A12Discs, large homolog 3 (neuroendocrine-dlg, *Drosophila*)Sodium channel, non-voltage-gated 1, gamma subunitST6 (alpha-*N*-acetyl-neuraminyl-2, 3-beta-galactosyl-1, 3) -N- acetylgalactosaminide alpha-2, 6-sialyltransferase 5Fc fragment of IgG, low affinity IIb, receptor (CD32)Table 8Best ranked genes for dataset "human pancreatic islets from normal and type II diabetic subjects (A)".Table 8Gene nameGlucuronidase, betaEnoyl-CoA delta isomerase 1C-terminal binding protein 1Inhibitor of DNA binding 2, dominant negative helix-loop-helix proteinHypoxanthine phosphoribosyltransferase 1Sialidase 1 (lysosomal sialidase)ATP-binding cassette, sub-family C (CFTR/MRP), member 4Aminolevulinate, delta-, synthase 1Suppressor of var1, 3-like 1 (*S. cerevisiae*)Flavin-containing monooxygenase 5Solute carrier family 26, member 6TGF-beta activated kinase 1/MAP3K7 binding protein 2Caveolin 2Nephrosis 1, congenital, Finnish type (nephrin)Fucosyltransferase 9 (alpha (1,3) fucosyltransferase)Cytidine deaminaseCytochrome P450, family 7, subfamily A, polypeptide 1Table 9Best ranked genes for dataset "human pancreatic islets from normal and type II diabetic subjects (B)".Table 9Gene nameAdenomatosis polyposis coli down-regulated 1Ribonuclease, RNase KTable 10Best ranked genes for dataset "human skeletal muscle-type II diabetes".Table 10Gene nameProtocadherin beta 3Leucine zipper, putative tumor suppressor family member 3USP6 N-terminal likeUbiquitously transcribed tetratricopeptide repeat containing, Y-linked
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Compute the ranking criterion for the i^th^ gene
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*Output*:

A gene-ranking list r

3.3. Identification of degree of essentiality and non-essentiality of genes {#s0035}
---------------------------------------------------------------------------

To identify significant and reliable targets, the work was concentrated on non-essential genes. Essential genes were ruled out based on the hits obtained from the Database of Essential Genes (DEG 10.9) (<http://tubic.tju.edu.cn/deg/>) [@bb0230]. Essential genes sustain an organism. Therefore, having them as a potential gene target may induce side effects of the drugs. Hence, it is important to identify only the non-essential genes which may be used as a potential drug target. [Table 11](#t0055){ref-type="table"}, [Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"} show the non-essential genes from the microarray dataset which is under studyTable 11Non-essential genes for dataset "GSE7146".Table 11Gene symbolGene nameG0S2G0/G1switch 2ACP1Acid phosphatase 1, solubleCCL27Chemokine (C-C motif) ligand 27JPH2Junctophilin 2KLK12Kallikrein-related peptidase 12S100A12S100 calcium binding protein A12DLG3Discs, large homolog 3 (neuroendocrine-dlg, *Drosophila*)SCNN1GSodium channel, non-voltage-gated 1, gamma subunitST6GALNAC5ST6 (alpha-*N*-acetyl-neuraminyl-2, 3-beta-galactosyl-1, 3) -*N*-acetylgalactosaminide alpha-2, 6-sialyltransferase 5FCGR2BFc fragment of IgG, low-affinity IIb, receptor (CD32)Table 12Non-essential genes for dataset "human pancreatic islets from normal and type II diabetic subjects (A)".Table 12Gene symbolGene nameHPRT1Hypoxanthine phosphoribosyltransferase 1ABCC4ATP-binding cassette, sub-family C (CFTR/MRP), member 4FMO5Flavin-containing monooxygenase 5CAV2Caveolin 2FUT3Fucosyltransferase 9 (alpha (1, 3) fucosyltransferase)CDACytidine deaminaseTable 13Non-essential genes for dataset "human pancreatic islets from normal and type II diabetic subjects (B)".Table 13Gene symbolGene nameAPCDD1Adenomatosis polyposis coli down-regulated 1RNASEKRibonuclease, RNase KTable 14Non-essential genes for dataset "human skeletal muscle-type II diabetes".Table 14Gene symbolGene nameUSP6NLLeucine zipper, putative tumor suppressor family member 3PROSAPIP1USP6 N-terminal like

3.4. Gene interaction studies {#s0040}
-----------------------------

After obtaining the non-essential genes from the top ranked coding genes for each of the datasets, gene regulatory network was constructed using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database [@bb0200]. The study was mainly done to observe the interaction between non-essential protein-coding genes with other proteins which are a result of biochemical events and/or electrostatic forces [@bb0115]. The function and activity of a protein are often modulated by other proteins with which it interacts.

### 3.4.1. Gene regulatory network of dataset "GSE7146" {#s0045}

In this dataset, out of the ten best coding genes obtained through the SVMRFE approach, only 5 genes (ACP1, FCGR2B, SCNN1G, CCL27, and DLG3) showed interaction with other protein coding genes ([Fig. 6](#f0030){ref-type="fig"}). The ACP1 showed a direct interaction with EPHA2, which is reported to increase the chance of myocardial infarction and reduce the survival rate of hyperglycemic mice [@bb0060]. LYN showed indirect interaction with ACP1 via EPHA2 and direct interaction with FCGR2B. Its kinase activation modulation has been reported to be a novel insulin receptor-potentiating agent. This potentiating agent produces a rapid-onset and a durable blood glucose-lowering activity in diabetic animals [@bb0160]. FCGR2B also showed direct interaction with PTPN6 which is been reported to negatively regulate insulin action on glucose homeostasis in the liver and muscle [@bb0220]. An analysis of DLG3 has shown its direct interaction with GRIN2A and GRIN2B. Both these genes have been reported to play a potential role in diabetes [@bb0055], [@bb0185], [@bb0210]. UBC has been reported to play a major role in the diabetes pathway [@bb0040], [@bb0080], [@bb0130] and its direct interaction with SCNN1G shows that SCNN1G may also play a role in diabetes pathway. CCL27 interacts with CCL25, a protein whose expression was shown to decrease significantly in diabetes [@bb0150].Fig. 6Gene regulatory network of dataset "GSE7146".Fig. 6

### 3.4.2. Gene regulatory network of dataset "human pancreatic islets from normal and type II diabetic subjects (A)" {#s0050}

Except for ABCC4 and FMO5, all the other four proteins showed a significant and strong interaction with other neighboring proteins ([Fig. 7](#f0035){ref-type="fig"}). Purine Nucleoside Phosphorylase (PNP) and Nucleoside Phosphate Kinase (NPK) have reportedly played a major role in diabetes either by positive or negative metabolic regulation [@bb0045]. These two molecules also showed interaction with the HPRT1 and the CDA. Caveolin has already been reported to mediate insulin signaling thereby affecting the glucose uptake [@bb0030]. In the other subgroup network FUT3 has three direct neighbors: FUT1, FUT2, and B4GALT1 of which the B4GALT1 expression level has been shown to be affected by hyperglycemia [@bb0125].Fig. 7Gene regulatory network of dataset "human pancreatic islets from normal and type II diabetic subjects (A)".Fig. 7

### 3.4.3. Gene regulatory network of the dataset "human pancreatic islets from normal and type II diabetic subjects (B)" {#s0055}

Both the protein coding genes in this dataset (RNASEK and APCDD1) have shown a significant interaction with the neighboring proteins ([Fig. 8](#f0040){ref-type="fig"}). The involvement of RNASEK in diabetes is still an unanswered question, but APCDD1 interaction with its neighbors shows that it may be involved in the pathophysiology of diabetes. LPAR6 (Lysophosphatidic Acid Receptor 6) interacting directly with APCCD1 has shown its activity with PPARγ which is a potential target for diabetes [@bb0190]. Aranda et al., in 2012 also showed that the DM/HG (*Diabetes mellitus*/High Glucose) reprograms signaling pathways in RECs (Retinal Endothelial Cells) to induce a state of LPA (Lysophosphatidic Acid) resistance. In the year 2000, Figueroa et al. [@bb0070] showed that alterations in LRP5 expression may be responsible for diabetes susceptibility. Therefore it may be a potential target for therapeutic intervention. It has been reported that Wnt/LRP5 (lipoprotein receptor-related protein 5) signaling contributes to the glucose-induced insulin secretion in the islets [@bb0075].Fig. 8Gene regulatory network of dataset "human pancreatic islets from normal and type II diabetic subjects (B)".Fig. 8

### 3.4.4. Gene regulatory network of dataset "human skeletal muscle-type II diabetes" {#s0060}

The two prominent protein coding genes (USP6NL and ProSAPiP1) as per SVMRFE analysis showed interaction with a different set of genes ([Fig. 9](#f0045){ref-type="fig"}). This selective network of ProSAPiP1 has not been reported till now, for diabetes. The three genes (SOS1, EGFR, and EGF) in the interaction network of USP6NL have shown its significance in connection with diabetes. SOS1 has shown its association with reference to the insulin action [@bb0020], in differential expression of EGFR which is a major impact on diabetes and associated diseases [@bb0005], [@bb0025], [@bb0135], [@bb0140], [@bb0205], [@bb0225]. Kasayama et al. [@bb0095] long back in 1989 reported that EGF deficiency occurs in *diabetes mellitus* hence insulin may be important in maintaining the normal level of EGF in the submandibular gland and plasma.Fig. 9Gene regulatory network of dataset "human skeletal muscle-type II diabetes".Fig. 9

3.5. Functional enrichment of significant genes implying pathway analysis {#s0065}
-------------------------------------------------------------------------

To further validate the involvement of the identified genes in type II diabetes, pathway enrichment was considered. This was solely meant for all the interacting proteins with the identified significant protein(s). The study was carried out using Biointerpreter, a web-based biological interpretation tool for Microarray data analysis (Genotypic Technology Pvt. Ltd., Bangalore, India). The pathway analysis showed that some of the interacting proteins were involved in pathways which were directly or indirectly associated with type II diabetes.

### 3.5.1. Pathway enrichment for the interacting proteins of the dataset "effect of insulin infusion on human skeletal muscle" {#s0070}

GRIN2A (Glutamate \[NMDA\] receptor subunit epsilon-1) and GRIN2B (Glutamate \[NMDA\] receptor subunit epsilon-2), the two proteins interacting mainly with the identified protein DLG3 have been shown to be involved in 3 different pathways viz. Neuroactive ligand-receptor interaction, circadian entrainment and Long-term potentiation ([Fig. 10](#f0050){ref-type="fig"}). The proteins present in the Neuroactive ligand-receptor interaction have shown a significant role in the pathobiology of obesity and type II diabetes [@bb0050]. The second pathway, circadian entrainment is the biological process that displays an endogenous oscillation of about 24 h. Studies show that exposure to light at night lowers glucose-stimulated insulin secretion due to a decrease in insulin secretory pulse mass. Potential mechanisms have been identified by which disturbances in the circadian rhythms due to modern lifestyle can lead to islet failure in the type II diabetes [@bb0175]. It has also been reported that the impaired energy utilization from insulin deficiency impairs a long-term potentiation in diabetes [@bb9000].Fig. 10Involvement of GRIN2A and GRIN2B in different pathways.Fig. 10

### 3.5.2. Pathway enrichment for the interacting proteins of the dataset "human pancreatic islets from normal and type II diabetic subjects (A)" {#s0075}

The protein B4GALT1, interacting with the identified protein FUT3 is involved in several metabolic pathways, connected to type II diabetes ([Fig. 11](#f0055){ref-type="fig"}). The protein B4GALT1 participates both in glycoconjugate and lactose biosynthesis. It has shown to be a biomarker in hepatocellular carcinoma, mainly caused due to the insulin resistance syndrome. Finally, the ailment manifests as obesity and later as diabetes [@bb0085].Fig. 11Involvement of B4GALT1 in different pathwaysFig. 11

### 3.5.3. Pathway enrichment for the interacting proteins of the dataset "human pancreatic islets from normal and type II diabetic subjects (B)" {#s0080}

The protein PNPT1 interacting with the RNASEK is reported to be involved in pyrimidine and purine metabolism and the RNA degradation ([Fig. 12](#f0060){ref-type="fig"}). Effects of the insulin regulation of purine and pyrimidine metabolism had shown to cause some late complications of the diabetic disease [@bb0170]. In 2009, Kocic et al. [@bb0100] reported that an impaired dsRNA metabolism may lead to increased levels of different sized RNAs in type II diabetic patients and may have an influence on further ineffective response against the different pathogens.Fig. 12Involvement of PNPT1 in different pathways.Fig. 12

### 3.5.4. Pathway enrichment for the interacting proteins of dataset "human skeletal muscle-type II diabetes" {#s0085}

EGFR protein interacting with the identified protein USP6NL has already been reported by many researchers to be involved in diabetes [@bb0005], [@bb0025], [@bb0135], [@bb0140], [@bb0205], [@bb0225]. With the pathway studies, it was identified that the main pathways in which EGFR is involved, is also leading directly to or indirectly to diabetes ([Fig. 13](#f0065){ref-type="fig"}). Hypoxia-inducible factor 1 alpha (HIF-1α) is regulated precisely by hypoxia and hyperglycemia. It had also been shown that the HIF-1α and glucose can sometimes influence each other [@bb0215]. It has been reported that the components of the MAPK/ERK pathway act as modifiers of the cellular insulin responsiveness. The insulin resistance was due to downregulation of the insulin-like receptor gene expression following persistent MAPK/ERK inhibition. The mechanism permits physiological adjustment of insulin sensitivity and the subsequent maintenance of the circulating glucose at appropriate levels [@bb1000]. MAPK and GnRh-Glp-1 pathways in the ileum have also been reported to be involved in the improvement of the blood glucose level [@bb0225].Fig. 13Involvement of EGFR in different pathways.Fig. 13

4. Conclusion {#s0090}
=============

Analysis of type II diabetes expression data from two different tissue samples i.e. skeletal muscle and pancreatic islet has given a deep insight into genes which may be possibly involved in the pathophysiology of the disease. The most discriminatory genes obtained in each dataset after complete analysis, have been found to be associated with diabetes either directly or indirectly. However, the majority of the genes have not been previously reported in association with diabetes. The genes identified in the current study viz. *FCGR2B*, *DLG3*, *SCNN1G*, *FUT3*, *HPRT1*, *APCDD1*, *USP6NL*, *ProSAPiP1* and *RNASEK* may act as a potential drug target. The significant pathways identified through the overall approach were Neuroactive ligand-receptor interaction, circadian entrainment, Long-term potentiation, pyrimidine and purine metabolism, dsRNA metabolism, MAPK/ERK pathway, and GnRh-Glp-1. This study gave the insight to focus on these associated pathways with the above-reported proteins to study in pathway models or mouse model to elucidate them as drug targets or markers for type II diabetes.
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